肺炎球菌ワクチンの世界市場レポート 2025年

肺炎球菌ワクチンの市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.3%で121億2,000万米ドルに成長します。予測期間の成長は、進化する肺炎球菌株、継続的な研究開発、予防接種の優先順位、ワクチンアクセスの拡大、人口の高齢化などに起因しています。予測期間中の主な動向には、多価ワクチンの開発、リスクのあるグループへのワクチン接種、ワクチンの有効性の向上、教育・啓発キャンペーン、乳幼児への予防接種が含まれます。

肺炎球菌ワクチン市場の成長は、肺炎球菌汚染の有病率の増加によって牽引されると予測されます。肺炎球菌汚染は、肺炎球菌または肺炎球菌によって引き起こされる様々な感染症を包含し、肺炎、血流感染症、耳感染症、副鼻腔感染症などの症状を引き起こします。肺炎球菌ワクチンは、抗体の産生を促し、肺炎球菌から身を守る上で重要な役割を果たします。これは、小児、高齢者、免疫力が低下している人など、弱い立場の人々にとって特に重要です。例えば、2022年1月に疾病対策予防センター（CDC）が発表した最近のデータでは、米国では肺炎球菌性肺炎により年間約15万人が入院しており、成人の市中肺炎のかなりの部分を占めていることが明らかになりました。

高齢化人口の増加は、肺炎球菌ワクチン市場の成長を促進する上で重要な役割を果たしています。高齢化とは、人口に占める高齢者の割合が時間の経過とともに増加する人口動態の変化を指します。肺炎などの肺炎球菌性疾患は、高齢者に多く、重症化する傾向があります。高齢になると免疫力が低下し、感染症にかかりやすくなります。例えば、2023年7月、英国を拠点とする高齢者のための慈善団体Age UKは、イングランドには65歳以上の高齢者が1,100万人いると報告しました。この数字は、今後5年間で10％、2043年までに32％増加すると予想されており、それぞれ110万人と350万人の増加となります。その結果、高齢化人口の増加が肺炎球菌ワクチン市場の拡大に寄与することになります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の肺炎球菌ワクチンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の肺炎球菌ワクチン市場：成長率分析
• 世界の肺炎球菌ワクチン市場の実績：規模と成長, 2019-2024
• 世界の肺炎球菌ワクチン市場の予測：規模と成長, 2024-2029, 2034F
• 世界の肺炎球菌ワクチン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の肺炎球菌ワクチン市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• プレベナー13
• シンフロリックス
• ニューモバックス23
• その他の製品
• 世界の肺炎球菌ワクチン市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内
• 筋肉内
• 皮下
• 世界の肺炎球菌ワクチン市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬局
• 地域診療所
• 公共衛生機関
• その他の流通チャネル
• 世界の肺炎球菌ワクチン市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小児
• 大人
• 世界の肺炎球菌ワクチン市場、プレベナー13の製品タイプ別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小児用処方
• 成人用処方
• 世界の肺炎球菌ワクチン市場、シンフロリックスの製品タイプ別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小児用処方
• 成人用処方
• 世界の肺炎球菌ワクチン市場、ニューモバックス23の製品タイプ別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単回投与バイアル
• プレフィルドシリンジ
• 世界の肺炎球菌ワクチン市場、その他の製品のサブセグメンテーション、製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• PCV15（ワクチンニューバンス）
• PCV20（プレベナー20）
• その他の地域肺炎球菌ワクチン

第7章 地域別・国別分析

• 世界の肺炎球菌ワクチン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の肺炎球菌ワクチン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 肺炎球菌ワクチン市場：競合情勢
• 肺炎球菌ワクチン市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Astellas Pharma Inc.
• CSL Limited
• Anhui Zhifei Longcom Biopharmaceutical Co. Ltd
• Serum Institute of India Private Limited
• Emergent BioSolutions Inc.
• Walvax Biotechnology Co. Ltd
• Biological E Limited
• Hualan Biological Engineering Inc.
• Beijing Minhai Biotechnology Limited Company
• NPO Petrovax Pharm LLC
• Vaxcyte Inc.
• Panacea Biotec Ltd
• Inventprise LLC
• Tergene Biotech Private Limited
• PnuVax Incorporated

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 肺炎球菌ワクチン市場2029：新たな機会を提供する国
• 肺炎球菌ワクチン市場2029：新たな機会を提供するセグメント
• 肺炎球菌ワクチン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

The pneumococcal vaccine is a vaccination designed to provide protection against severe pneumococcal infections caused by Streptococcus pneumoniae bacteria, including pneumonia, meningitis, and sepsis. It is particularly effective in preventing one of the most common causes of meningitis and other illnesses in infants, such as acute ear infections.

The primary pneumococcal vaccines include Prevnar 13, Synflorix, Pneumovax23, and others. Prevnar 13 is a pneumococcal conjugate vaccine containing 13 distinct strains of Streptococcus pneumoniae. It is administered to children and tested on immunocompromised patients to prevent pneumococcal disease. The vaccine can be administered through intravenous, intramuscular, and subcutaneous routes and is distributed through pharmacies, community clinics, public health agencies, and other channels to end-users such as pediatrics and adults.

The pneumococcal vaccine market research report is one of a series of new reports from The Business Research Company that provides pneumococcal vaccine market statistics, including pneumococcal vaccine industry global market size, regional shares, competitors with a pneumococcal vaccine market share, detailed pneumococcal vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the pneumococcal vaccine industry. This pneumococcal vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pneumococcal vaccine market size has grown strongly in recent years. It will grow from $8.94 billion in 2024 to $9.49 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to discovery of streptococcus pneumoniae, public health concern, early vaccination efforts, healthcare advancements, vaccine policy changes

The pneumococcal vaccine market size is expected to see strong growth in the next few years. It will grow to $12.12 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to evolving pneumococcal strains, continued research and development, immunization priorities, expanded vaccine access, population aging. Major trends in the forecast period include multivalent vaccine development, vaccination in at-risk group, boosting vaccine efficacy, education and awareness campaigns, targeting infant immunization.

The growth of the pneumococcal vaccine market is anticipated to be driven by the increasing prevalence of pneumococcal contamination. Pneumococcal contamination encompasses various infections caused by Streptococcus pneumoniae or pneumococcus bacteria, leading to conditions such as pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine plays a crucial role in stimulating the production of antibodies, offering protection against pneumococcal bacteria. This is particularly vital for vulnerable populations, including children, the elderly, and individuals with weakened immune systems. For instance, recent data from the Center for Disease Control and Prevention (CDC) in January 2022 revealed that pneumococcal pneumonia results in approximately 150,000 hospitalizations annually in the United States, representing a substantial portion of adult community-acquired pneumonia cases.

The increasing aging population is playing a significant role in driving the growth of the pneumococcal vaccine market. An aging population refers to a demographic shift where the proportion of elderly individuals in a population rises over time. Pneumococcal diseases, such as pneumonia, tend to be more common and severe in older adults. As people age, their immune systems weaken, making them more vulnerable to infections. For example, in July 2023, Age UK, a UK-based charity for older individuals, reported that there are 11 million people over the age of 65 in England. This figure is expected to grow by 10% within the next five years and by 32% by 2043, representing increases of 1.1 million and 3.5 million individuals, respectively. As a result, the growing aging population will contribute to the expansion of the pneumococcal vaccine market.

Major companies in the pneumococcal vaccine market are actively innovating new products. For instance, Merck & Co Inc., a prominent pharmaceutical company, introduced the V116 vaccine in July 2023. Designed to target eight distinct serotypes of Streptococcus pneumoniae responsible for adult pneumococcal disease, V116 has exhibited superior immunogenicity compared to other vaccines in adult populations. Notably, the U.S. Food and Drug Administration (FDA) has designated V116 as a breakthrough therapy, currently advancing through Phase 3 development.

Conjugate vaccines are gaining prominence among major companies in the pneumococcal vaccine market, offering enhanced protection by targeting multiple serotypes. Pfizer, a leading pharmaceutical company, launched PREVNAR 20 in April 2023, a conjugate vaccine designed to protect against the 20 pneumococcal serotypes responsible for the majority of pneumococcal diseases. The development of such advanced vaccines underscores the commitment to comprehensive preventive measures.

In August 2022, GSK plc strategically acquired Affinivax, Inc., a clinical-stage biopharmaceutical company, for an undisclosed amount. This acquisition provides GSK plc with access to innovative technologies, including the Multiple Antigen Presenting System (MAPS), and the 24-valent pneumococcal vaccine candidate, further solidifying its position in the pneumococcal vaccine market.

Major companies operating in the pneumococcal vaccine market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Astellas Pharma Inc., CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, Inventprise LLC, Tergene Biotech Private Limited, PnuVax Incorporated, SK Bioscience Co Ltd

North America was the largest region in the pneumococcal vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pneumococcal vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pneumococcal vaccine market consists of sales of vaxneuvance, prevnar 20, pneumococcal conjugate vaccines (PCV)10, and pneumococcal conjugate vaccines (PCV)7. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pneumococcal Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pneumococcal vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pneumococcal vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pneumococcal vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Prevnar 13; Synflorix; Pneumovax23; Other Products
• 2) By Route of Administration: Intravenous; Intramuscular; Subcutaneous
• 3) By Distribution Channel: Pharmacies; Community Clinics; Public Health Agencies; Other Distribution Channels
• 4) By End User: Pediatrics; Adults
• Subsegments:
• 1) By Prevnar 13: Pediatric Formulation; Adult Formulation
• 2) By Synflorix: Pediatric Formulation; Adult Formulation
• 3) By Pneumovax23: Single-Dose Vials; Pre-Filled Syringes
• 4) By Other Products: PCV15 (Vaxneuvance); PCV20 (Prevnar 20); Other Regional Pneumococcal Vaccines
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; Sanofi S.A.; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pneumococcal Vaccine Market Characteristics

3. Pneumococcal Vaccine Market Trends And Strategies

4. Pneumococcal Vaccine Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Pneumococcal Vaccine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Pneumococcal Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Pneumococcal Vaccine Market Growth Rate Analysis
• 5.4. Global Pneumococcal Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Pneumococcal Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Pneumococcal Vaccine Total Addressable Market (TAM)

6. Pneumococcal Vaccine Market Segmentation

• 6.1. Global Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prevnar 13
• Synflorix
• Pneumovax23
• Other Products
• 6.2. Global Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Intramuscular
• Subcutaneous
• 6.3. Global Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmacies
• Community Clinics
• Public Health Agencies
• Other Distribution Channels
• 6.4. Global Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatrics
• Adults
• 6.5. Global Pneumococcal Vaccine Market, Sub-Segmentation Of Prevnar 13, By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric Formulation
• Adult Formulation
• 6.6. Global Pneumococcal Vaccine Market, Sub-Segmentation Of Synflorix, By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric Formulation
• Adult Formulation
• 6.7. Global Pneumococcal Vaccine Market, Sub-Segmentation Of Pneumovax23, By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Dose Vials
• Pre-Filled Syringes
• 6.8. Global Pneumococcal Vaccine Market, Sub-Segmentation Of Other Products, By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PCV15 (Vaxneuvance)
• PCV20 (Prevnar 20)
• Other Regional Pneumococcal Vaccines

7. Pneumococcal Vaccine Market Regional And Country Analysis

• 7.1. Global Pneumococcal Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Pneumococcal Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pneumococcal Vaccine Market

• 8.1. Asia-Pacific Pneumococcal Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pneumococcal Vaccine Market

• 9.1. China Pneumococcal Vaccine Market Overview
• 9.2. China Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pneumococcal Vaccine Market

• 10.1. India Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pneumococcal Vaccine Market

• 11.1. Japan Pneumococcal Vaccine Market Overview
• 11.2. Japan Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pneumococcal Vaccine Market

• 12.1. Australia Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pneumococcal Vaccine Market

• 13.1. Indonesia Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pneumococcal Vaccine Market

• 14.1. South Korea Pneumococcal Vaccine Market Overview
• 14.2. South Korea Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pneumococcal Vaccine Market

• 15.1. Western Europe Pneumococcal Vaccine Market Overview
• 15.2. Western Europe Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pneumococcal Vaccine Market

• 16.1. UK Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pneumococcal Vaccine Market

• 17.1. Germany Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pneumococcal Vaccine Market

• 18.1. France Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pneumococcal Vaccine Market

• 19.1. Italy Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pneumococcal Vaccine Market

• 20.1. Spain Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pneumococcal Vaccine Market

• 21.1. Eastern Europe Pneumococcal Vaccine Market Overview
• 21.2. Eastern Europe Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pneumococcal Vaccine Market

• 22.1. Russia Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pneumococcal Vaccine Market

• 23.1. North America Pneumococcal Vaccine Market Overview
• 23.2. North America Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pneumococcal Vaccine Market

• 24.1. USA Pneumococcal Vaccine Market Overview
• 24.2. USA Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pneumococcal Vaccine Market

• 25.1. Canada Pneumococcal Vaccine Market Overview
• 25.2. Canada Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pneumococcal Vaccine Market

• 26.1. South America Pneumococcal Vaccine Market Overview
• 26.2. South America Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pneumococcal Vaccine Market

• 27.1. Brazil Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pneumococcal Vaccine Market

• 28.1. Middle East Pneumococcal Vaccine Market Overview
• 28.2. Middle East Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pneumococcal Vaccine Market

• 29.1. Africa Pneumococcal Vaccine Market Overview
• 29.2. Africa Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pneumococcal Vaccine Market Competitive Landscape And Company Profiles

• 30.1. Pneumococcal Vaccine Market Competitive Landscape
• 30.2. Pneumococcal Vaccine Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Pneumococcal Vaccine Market Other Major And Innovative Companies

• 31.1. Astellas Pharma Inc.
• 31.2. CSL Limited
• 31.3. Anhui Zhifei Longcom Biopharmaceutical Co. Ltd
• 31.4. Serum Institute of India Private Limited
• 31.5. Emergent BioSolutions Inc.
• 31.6. Walvax Biotechnology Co. Ltd
• 31.7. Biological E Limited
• 31.8. Hualan Biological Engineering Inc.
• 31.9. Beijing Minhai Biotechnology Limited Company
• 31.10. NPO Petrovax Pharm LLC
• 31.11. Vaxcyte Inc.
• 31.12. Panacea Biotec Ltd
• 31.13. Inventprise LLC
• 31.14. Tergene Biotech Private Limited
• 31.15. PnuVax Incorporated

32. Global Pneumococcal Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pneumococcal Vaccine Market

34. Recent Developments In The Pneumococcal Vaccine Market

35. Pneumococcal Vaccine Market High Potential Countries, Segments and Strategies

• 35.1 Pneumococcal Vaccine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Pneumococcal Vaccine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Pneumococcal Vaccine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer